52 results
8-K
EX-99.1
AUTL
Autolus Therapeutics plc
17 May 24
Results of Operations and Financial Condition
8:27am
is a next-generation product candidate for multiple myeloma, which includes two CARs for the multiple myeloma targets, BCMA and CD19. Initial data … – Phase 1 MAGNETO Study o AUTO6NG contains a CAR that targets GD2 alongside additional programming modules to enhance the activity and persistence
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
for multiple myeloma, which comprises two independent CARs for the multiple myeloma targets, BCMA and CD19. We have developed an optimized BCMA CAR which … will preserve a portion of the patient’s normal, healthy T cells to maintain immunity. It targets an antigen, TRBC1 found on approximately 40% of T cell
10-K
2023 FY
EX-10.12
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
will not be considered Sublicensees. 1.205 “Target” means one or more biological targets identified by BioNTech in respect of which BioNTech wishes … AE Licensed Products. (b) Nomination of Targets. If BioNTech wishes to conduct the Evaluation or exercise its Activity Enhancement Option, in each case
8-K
EX-99.1
AUTL
Autolus Therapeutics plc
14 Mar 24
Results of Operations and Financial Condition
12:32pm
CARs for the multiple myeloma targets, BCMA and CD19. Initial data from the MCARTY Phase 1 study in multiple myeloma presented at ASH in December 2023 … in Neuroblastoma – Phase 1 MAGNETO Study AUTO6NG contains a CAR that targets GD2 alongside additional programming modules to enhance the activity
8-K
d9vts9zdgu1dpkkr
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
8-K
EX-99.1
b5a3hy
11 Dec 23
Regulation FD Disclosure
8:31am
10-Q
z978zuuyb pi5v
9 Nov 23
Quarterly report
4:18pm
6-K
EX-99.2
uss pr4ov
2 Nov 23
Index to Condensed Consolidated Financial Statements
4:26pm
6-K
EX-99.3
xceupskjti lec
2 Nov 23
Index to Condensed Consolidated Financial Statements
4:26pm
6-K
EX-99.1
2fintj6 kin1b
2 Nov 23
Index to Condensed Consolidated Financial Statements
4:26pm
6-K
EX-99.3
pqq2x
3 Aug 23
Index to Condensed Consolidated Financial Statements
4:32pm
6-K
EX-99.1
1ld0etyf4ww
3 Aug 23
Index to Condensed Consolidated Financial Statements
4:32pm
6-K
EX-99.2
nm8ku8dggdh3 9r
3 Aug 23
Index to Condensed Consolidated Financial Statements
4:32pm
6-K
EX-99.1
oijkd1x
4 May 23
Index to Condensed Consolidated Financial Statements
4:04pm
6-K
EX-99.2
rh8avr8
4 May 23
Index to Condensed Consolidated Financial Statements
4:04pm
6-K
EX-99.3
0e7u9
4 May 23
Index to Condensed Consolidated Financial Statements
4:04pm
424B5
6ank ukq4p33
9 Dec 22
Prospectus supplement for primary offering
5:40pm
424B5
it6aioxtor
8 Dec 22
Prospectus supplement for primary offering
4:10pm
6-K
EX-99.3
kuz9e
3 Nov 22
Index to Condensed Consolidated Financial Statements
10:31am